^Ensinger HA, Doods HN, Immel-Sehr AR, et al. (1993). "WAL 2014--a muscarinic agonist with preferential neuron-stimulating properties". Life Sciences. 52 (5–6): 473–80.
doi:
10.1016/0024-3205(93)90304-L.
PMID8441328.
^Walland A, Burkard S, Hammer R, Tröger W (1997). "In vivo consequences of M1-receptor activation by talsaclidine". Life Sciences. 60 (13–14): 977–84.
doi:
10.1016/S0024-3205(97)00037-4.
PMID9121364.
^
abWienrich M, Meier D, Ensinger HA, et al. (April 2001). "Pharmacodynamic profile of the M1 agonist talsaclidine in animals and man". Life Sciences. 68 (22–23): 2593–600.
doi:
10.1016/S0024-3205(01)01057-8.
PMID11392631.
^Adamus WS, Leonard JP, Tröger W (1995). "Phase I clinical trials with WAL 2014, a new muscarinic agonist for the treatment of Alzheimer's disease". Life Sciences. 56 (11–12): 883–90.
doi:
10.1016/0024-3205(95)00024-Z.
PMID10188789.
^Ensinger HA, Doods HN, Immel-Sehr AR, et al. (1993). "WAL 2014--a muscarinic agonist with preferential neuron-stimulating properties". Life Sciences. 52 (5–6): 473–80.
doi:
10.1016/0024-3205(93)90304-L.
PMID8441328.
^Walland A, Burkard S, Hammer R, Tröger W (1997). "In vivo consequences of M1-receptor activation by talsaclidine". Life Sciences. 60 (13–14): 977–84.
doi:
10.1016/S0024-3205(97)00037-4.
PMID9121364.
^
abWienrich M, Meier D, Ensinger HA, et al. (April 2001). "Pharmacodynamic profile of the M1 agonist talsaclidine in animals and man". Life Sciences. 68 (22–23): 2593–600.
doi:
10.1016/S0024-3205(01)01057-8.
PMID11392631.
^Adamus WS, Leonard JP, Tröger W (1995). "Phase I clinical trials with WAL 2014, a new muscarinic agonist for the treatment of Alzheimer's disease". Life Sciences. 56 (11–12): 883–90.
doi:
10.1016/0024-3205(95)00024-Z.
PMID10188789.